{
  "nctId": "NCT01258075",
  "briefTitle": "Colesevelam for Children With Type 2 Diabetes",
  "officialTitle": "Colesevelam Oral Suspension as Monotherapy or Add-on to Metformin Therapy in Pediatric Subjects With Type 2 Diabetes Mellitus",
  "protocolDocument": {
    "nctId": "NCT01258075",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2011-08-30",
    "uploadDate": "2020-11-25T14:10",
    "size": 10282383,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT01258075/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 236,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2011-02-24",
    "completionDate": "2020-04-21",
    "primaryCompletionDate": "2019-11-01",
    "firstSubmitDate": "2010-12-09",
    "firstPostDate": "2010-12-10"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Diagnosis of type 2 diabetes mellitus, as defined by the American Diabetes Association;\n* Written informed consent of study participation\n* Males and females aged 10 to 17 years, inclusive, at randomization (randomization must occur before 18th birthday);\n* HbA1c at screening between 7.0% and 10.0%, inclusive;\n* Fasting C-peptide \\>0.6 ng/mL; and\n* Anti-diabetic treatment at screening:\n\n  * Treatment-naïve or untreated; OR\n  * On metformin monotherapy: Metformin monotherapy has been initiated prior to screening.\n\nExclusion Criteria:\n\n* Fasting plasma glucose \\>270 mg/dL;\n* Diagnosis of type 1 diabetes;\n* History of more than one episode of ketoacidosis after the initial diagnosis of type 2 diabetes mellitus;\n* Clinical laboratory assessments/evaluations, eg. autoimmune markers, aminotransferases, triglycerides, creatinine clearance, and Hb variants, that are not within the protocol-defined parameters\n* Systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥95 mmHg\n* Use of medications not allowed by protocol-defined parameters, eg. insulin or any medication that affects insulin sensitivity or secretion, growth hormones/somatotropin, or anabolic steroids\n* Genetic syndrome or disorder known to affect glucose\n* Participation in a weight loss program or another interventional research study within 60 days;\n* Female participants who are lactating, pregnant, or plan to become pregnant within 1 year of screening;\n* Female participants who are sexually active and unwilling to use appropriate contraception for the duration of the study;\n* History of bowel obstruction;\n* Other significant organ system illness or condition (including psychiatric or developmental disorder) that, in the opinion of the Investigator, would prevent full participation",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "10 Years",
    "maximumAge": "17 Years",
    "stdAges": [
      "CHILD"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percent Change in Hemoglobin A1c (HbA1c) From Baseline to Month 6",
        "description": "The percent change in HbA1c from baseline to Month 6 was assessed with the last observation after 1 month before any rescue therapy carried forward.",
        "timeFrame": "Baseline to Month 6 post-dose"
      }
    ],
    "secondary": [
      {
        "measure": "Percent Change in Hemoglobin A1c (HbA1c) From Baseline to Month 12",
        "description": "The percent change in HbA1c from baseline to Month 6 was assessed with the last observation after 1 month before any rescue therapy carried forward.",
        "timeFrame": "Baseline to Month 12 post-dose"
      },
      {
        "measure": "Change in Fasting Plasma Glucose (FPG) From Baseline to Month 12",
        "description": "Change from baseline was assessed for FPG values at Month 6 and Month 12 categorical time points.",
        "timeFrame": "Baseline to Month 12 post-dose"
      },
      {
        "measure": "Number of Participants Achieving a Response to Therapy to Month 12",
        "description": "Participants achieving a response to therapy, ie, glycemic control, were assessed with the last observation after 1 month before any rescue therapy carried forward at Month 6 and Month 12. Response to therapy was defined as HbA1c \\<7.0% or \\<6.5%, reduction in HbA1c ≥0.7% or ≥0.5% from baseline, and/or reduction in FPG ≥30 mg/dL from baseline.",
        "timeFrame": "Baseline to Month 12 post-dose"
      },
      {
        "measure": "Percent Change From Baseline to Month 6 in Plasma Lipids",
        "description": "The percent change in plasma lipids from baseline to Month 6 was assessed with the last observation after 1 month before any rescue therapy carried forward.",
        "timeFrame": "Baseline to Month 6 post-dose"
      },
      {
        "measure": "Percent Change From Baseline to Month 6 in Triglycerides",
        "description": "The percent change in triglycerides from baseline to Month 6 was assessed with the last observation after 1 month before any rescue therapy carried forward.",
        "timeFrame": "Baseline to Month 6 post-dose"
      },
      {
        "measure": "Number of Participants Requiring Rescue Medication Who Initially Met Rescue Criteria",
        "description": "Rescue criteria was defined as HbA1c levels ≥8.5% after 3 months or ≥7.5% after 6 months (≥173 days) (confirmed persistent hyperglycemia) of study medication treatment, as measured by the central laboratory.",
        "timeFrame": "Baseline to Month 12 post-dose"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 6,
      "otherCount": 0,
      "totalCount": 7
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 69,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:29:11.067Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}